Institutionalizing Externalization At Big Pharma – The Third Leg
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
You may also be interested in...
Too Big To Succeed: Where Are Large Pharmas Heading?
Company scale is a negative predictor of value creation among biopharmaceutical companies, says a new analysis by L.E.K. Consulting, and industry’s largest companies have simply become too large to generate significant shareholder return going forward. How can the largest pharmaceutical companies adapt to an environment where they’ve become too big to succeed?
Deals Of The Week: United Therapeutics/Ascendis, Baxter/Onconova, Bionomics/Eclipse
The growing importance of emerging markets was a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.